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Correction of a Genetic Defect
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Combined Cell and Gene Therapy
plementation (Hochedlinger and Jaenisch, 2002). Be-
cause somatic nuclear transfer allows the isolation of
ES cells genetically matched to diseased individuals,
this “therapeutic cloning” or “nuclear transplantation
therapy” (Vogelstein et al., 2002) approach has been
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We chose a mouse strain with a defined genetic disor-
der to develop a model that combines therapeutic clon-Summary
ing with gene and cell therapy (Figure 1). The basic steps
involve (1) nuclear transfer of a somatic cell nucleus fromImmune-deficient Rag2/ mice were used as nuclear
the affected donor mouse into an enucleated oocyte,donors for transfer into enucleated oocytes, and the
(2) activation and cultivation of the NT embryo to theresulting blastocysts were cultured to isolate an iso-
blastocyst stage, (3) isolation and culture of ES cellsgenic embryonic stem cell line. One of the mutated
(ntES) from the blastocyst, (4) repair of the genetic defectalleles in the Rag2/ ES cells was repaired by homolo-
by homologous recombination, (5) differentiation of thegous recombination, thereby restoring normal Rag2
repaired ntES cells in vivo, via tetraploid embryo com-gene structure. Mutant mice were treated with the
plementation, or in vitro into hematopoietic stem cellsrepaired ES cells in two ways. (1) Immune-competent
(HSCs), and (6) transplantation of the “repaired” HSCsmice were generated from the repaired ES cells by
into affected donor mice. As a model we selected thetetraploid embryo complementation and were used as
severe combined immune deficiency caused by inacti-bone marrow donors for transplantation. (2) Hemato-
vation of the Rag2 recombinase resulting in the com-poietic precursors were derived by in vitro differentia-
plete absence of mature B and T cells in the lymphoidtion from the repaired ES cells and engrafted into mu-
organs and absence of immunoglobulins from the serumtant mice. Mature myeloid and lymphoid cells as well
of the mouse (Shinkai et al., 1992). The immune defi-as immunoglobulins became detectable 3–4 weeks
ciency in Rag1 and 2 knockout mice resembles Omennafter transplantation. Our results establish a paradigm
syndrome and the severe combined immune deficiencyfor the treatment of a genetic disorder by combining
seen in humans homozygous for mutations at eithertherapeutic cloning with gene therapy.
RAG1 or RAG2 (Notarangelo et al., 1999). Rag2 null mice
remain viable and have a normal lifespan when housedIntroduction
in a clean animal facility. Importantly, their lymphoid
system can be restored by transplantation of isogenic
The development of somatic cell nuclear transfer (NT) bone marrow or fetal liver hematopoietic stem cells from
techniques to produce viable cloned mammals (Waka- wild-type mice. Therefore, the Rag2 mutant mice pro-
yama et al., 1998; Wilmut et al., 1997) demonstrated the vide a sensitive experimental system to detect func-
ability of oocyte cytoplasm to reprogram a somatic do- tional engraftment of hematopoietic stem cells derived
nor nucleus to a pluripotent state (Rideout et al., 2001). from genetically modified ES cells.
Additionally, embryonic stem (ES) cells have been de- Therapeutic cloning for treating an immune deficiency
rived from blastocysts generated by transfer of somatic depends on the in vitro differentiation of ntES cells into
cell nuclei (Kawase et al., 2000; Munsie et al., 2000; functional hematopoietic cells that are able to provide
Wakayama et al., 2001; Hochedlinger and Jaenisch, long-term repopulation of the lymphoid compartment
2002). These “NT ES” cells have been shown to differen- after transplantation. ES cells can be differentiated in
tiate in vitro into cells of several different developmental vitro into hematopoietic precursors, as demonstrated
lineages including neurons, blood, and cardiac muscle. by the appearance of blood islands in embryoid bodies
In addition, NT ES cells were shown to contribute exten- (EB) and the isolation of several types of primitive hema-
sively to diploid chimeras (Wakayama et al., 2001) and topoietic colonies from EBs (Keller et al., 1993; Wiles
to generate fertile mice following tetraploid embryo com- and Keller, 1991). While there have been reports of re-
population of hematopoietic lineages in lethally irradi-
ated mice, efficient methods for functional, long-term,5 Correspondence: jaenisch@wi.mit.edu
6 These authors contributed equally to this work. and multilineage hematopoietic engraftment from ES
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Figure 1. Scheme for Therapeutic Cloning
Combined with Gene and Cell Therapy
A piece of tail from a mouse homozygous for
the recombination-activating gene 2 (Rag2)
mutation was removed and cultured. After
fibroblast-like cells grew out, they were used
as donors for nuclear transfer by direct injection
into enucleated MII oocytes using a Piezo-
electric-driven micromanipulator. Embryonic
stem (ES) cells isolated from the NT-derived
blastocysts were genetically repaired by homo-
logous recombination. After repair, the ntES
cells were differentiated in vitro into embryoid
bodies (EBs), infected with the HoxB4iGFP
retrovirus, expanded, and injected into the
tail vein of irradiated, Rag2-deficient mice.
cells have been lacking (Hole et al., 1996; Muller and yama et al., 2001), the rate of ES cell derivation from the
cloned blastocysts was comparable (3% versus 6%).Dzierzak, 1993; Potocnik et al., 1997). Recently, we
showed that expression of the leukemia-associated The resulting cell line, Rag2/ ntES, was tested for
pluripotency by the most stringent method available,BCR/ABL oncogene in differentiating ES cells enabled
engraftment of mice with leukemic lymphoid and my- namely, tetraploid embryo complementation (Eggan et
al., 2001; Hochedlinger and Jaenisch, 2002; Nagy eteloid elements (Perlingeiro et al., 2001). The BCR/ABL
experiments also demonstrated that the target cell re- al., 1993). ES cell complementation of tetraploid host
blastocysts results in the embryo being completely de-quired for our purpose, the lymphoid-myeloid HSC, was
present by day 5 in embryoid bodies derived from ES rived from the injected ES cells while the tetraploid host
cells contribute to the placenta (Wang et al., 1997). Wecells (Perlingeiro et al., 2001). In the current study, we
used an improved method for deriving normal hemato- previously showed that injection of wild-type F1 ES cells
into tetraploid blastocysts resulted in viable mice frompoietic progenitors by genetic modification of ES cells
with the Homeobox gene HoxB4, which provides a 4%–10% of the manipulated embryos (Eggan et al.,
2001) and that injection of ntES cells derived from F1means for functional hematopoietic reconstitution of le-
thally irradiated mice (Kyba et al., 2002 [this issue of lymphocytes also gave rise to viable mice (Hochedlinger
and Jaenisch, 2002). Similarly, the Rag2/ ntES lineCell]). Here we show that “repaired” ES cells derived
from a Rag2-deficient mouse can be differentiated into generated four viable pups out of 14 reconstituted tetra-
ploid blastocysts (28%), indicating that this line wasfunctional hematopoietic stem cells that restore immune
function when transplanted into adult Rag2 mutant mice. pluripotent and able to efficiently generate all somatic
cell types (Table 1).
Results
Repair of the Rag2 Mutation
in the Rag2/ ntES LineNT and Pluripotent ntES Cell Derivation
The immunodeficient mouse model for Rag2 deficiency We restored Rag2 function in the Rag2/ ntES line by
homologous recombination followed by cre recombi-has previously been generated by deletion of part of
the third coding exon and the insertion of a pMCneo nase-mediated removal of the loxP-flanked selectable
marker (Hygtk) (Figure 2A). Because the selectablecassette transcribed in the opposite orientation (Figure
2A; Shinkai et al., 1992). Tail-tip cells from a Rag2/ marker was positioned close to the site of the insertion/
deletion mutation of the Rag2 null allele (approximatelymale mouse (129Sv/Ev X C57Bl/6 [129B6F1]) were used
as nuclear donors for transfer into enucleated MII (meta- 0.5 kb), recombination occurring between the site of the
Hygtk cassette and pMC-Neo insertion in the mutantphase II) oocytes by the “Honolulu” method (Wakayama
et al., 1998). The development of the tail-tip NT embryos allele was unlikely. Southern analysis of DNA from Hyg-
resistant subclones was performed with a 5 probe (Fig-to the blastocyst stage was usually delayed compared to
in vitro activated and cultured parthenogenetic embryos ure 2B) to check for homologous recombination and by
an internal probe to exclude random integrations (data(4.5 and 3.5 dpc, respectively). Approximately 13% (27
of 202) of the reconstructed oocytes developed into not shown). Correct targeting was found in 58/288 (20%)
of the subclones, demonstrating that NT-derived ESblastocysts, and of these one generated an ES cell line
(Rag2/ ntES). While this rate of blastocyst formation cells can be effectively targeted by homologous recom-
bination like normal mouse ES cells.following nuclear transfer from tail-tip cells was lower
than that reported by others (13% versus 38%; Waka- Two targeted subclones (#4 and #132) were transiently
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Figure 2. Repair of the Rag2 Mutant Allele
(A) Scheme for repairing the knockout allele of Rag2. The top line illustrates the mutant allele, showing the replacement of much of Exon 3
by the selectable pMCNeo cassette. The repair contruct for targeting is shown below with the LoxP-flanked selectable CMV Hygtk cassette
inserted into a SalI site between exons 2 and 3 (CMV, cytomegalovirus promoter; Hygtk, hygromycin resistance/thymidine kinase fusion gene).
The next two lines illustrate the structure of the targeted allele and the repaired allele (after Cre recombinase-mediated loop-out of CMV-
Hygtk). Relevant restriction sites and 5 and internal probes for Southern analysis are shown. Exons are shown as open rectangles (exons 1
and 2 are not to scale). The scale is as shown (kb, kilobase).
(B) Southern analysis of ES cell DNA. Ten micrograms of each DNA was digested by AflII and SphI overnight, electrophoresed on a 0.85%
agarose gel, blotted to nylon membrane, and probed with 32P-labeled 5 probe. (WT, wild-type; Rag2/ ntES, nuclear transfer-derived ES
cells; 4, 132, targeted subclones; 4-4, 132-1, 132-2, and 132-3, repaired subclones).
transfected with a cre-expressing plasmid (pCrePAC) Southern analysis with the 5 probe on DNA from gan-
cyclovir-resistant subclones detected the loss of the(Taniguchi et al., 1998) and selected with gancyclovir
for loop-out of the Hygtk-selectable marker (Figure 2A). selectable Hygtk marker and no additional gene rearrange-
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as HSC donors (from neonate peripheral blood and boneTable 1. Mice Derived from Tetraploid Embryo Complementation
with Rag2/ and Rag2R/ ntES Cell Lines marrow from 1-month-old mice) for transplantation back
into sublethally irradiated Rag2 null mice. After two to# 4n Blastocysts Live Pups
three months the mice were bled and analyzed by FACS,ES Line Injected (Number of Neonatal Death)
which showed the presence of mature B and T cells
Rag2/ 14 4 (0)
(Figure 3C). The relative level of mature B and T cellsRag2R/ 226 38 (9)
(30.3% 9.2% and 27.7% 6.1% [n 6], respectively)
in total peripheral blood mononuclear cells (PBMCs) was
similar to that of normal mice. This indicates that the
ments in the repaired allele (Figure 2B). This restored repaired ntES cells gave rise to normal bone marrow
normal Rag2 gene structure on one allele and left a that restored the lymphoid system after transplantation
single loxP site in the second intron (this allele was into Rag2 mutant mice. The donor HSCs in these experi-
designated Rag2R). In order to assess whether the gene ments were generated during the course of normal
targeting had restored proper gene function, mice were mouse development in the tetraploid complementation
generated from the repaired ES cells. embryos. The restoration of immune function in the re-
cipients indicated that bone marrow cells derived from
the “repaired” ES cell mice were able to fully functionTetraploid Embryo Complementation
after transplantation into Rag2 mutant host animals.with the Rag2R/ ES Lines
We next assessed whether in vitro differentiation ofThe genetically repaired ntES cells were used to gener-
the repaired ES cells instead of in vivo formation ofate mice by tetraploid embryo complementation (Hoched-
normal bone marrow would allow the generation of de-linger and Jaenisch, 2002) in which the embryo proper
finitive hematopoietic stem cells that could be used foris entirely derived from the ntES cells, and the extraem-
transplantation into mutant animals.bryonic lineages are derived from the tetraploid host
blastocyst. Therefore, successful correction of the Rag2
In Vitro Differentiation of Rag2R/ ntES Cellsmutation can be directly assessed by analyzing immune
and Transplantation into Rag2 Mutant Micefunction in the “repaired” ES cell-derived animals. Fur-
Therapeutic cloning requires that the ntES cells be dif-thermore, neonate blood (analogous to cord blood
ferentiated in vitro into the relevant tissue or cell typestransplants) or adult bone marrow harvested from the
followed by transplantation into affected nuclear do-animals can be transplanted into adult Rag2 mutant
nors. We recently established a method for in vitro differ-recipients to evaluate their potential to colonize the
entiation of ES cells into embryonic hematopoietic stemlymphoid compartment and correct the immune defi-
cells that could be used for long-term lymphoid andciency. We injected 226 tetraploid blastocysts with four
myeloid engraftment of lethally irradiated mice (Kyba etdifferent repaired subclones (4-4, 132-1, 132-2, and
al., 2002 [this issue of Cell]). We used this system to132-3) and obtained 38 live pups (16%) delivered by
attempt restoration of immune function in immunodefi-C-section (Table 1). Of these, nine died shortly after
cient Rag2/ mice with the Rag2R/ ntES cells. Afterdelivery, but the rest were viable, healthy, and fertile.
differentiating the Rag2R/ ntES cells into EBs for 6Thus, the repaired Rag2R/ ntES cells remained fully
days, we introduced the HoxB4 and GFP (green fluores-pluripotent, with no loss of developmental potential.
cent protein) genes by retroviral transduction with theWe analyzed the lymphoid cells of the Rag2R/ ntES
MSCVHoxB4iGFP vector (Kyba et al., 2002 [this issuemice derived by tetraploid embryo complementation to
of Cell]). The infected cells were then cultured for 14 daysdetermine whether the repaired allele was functional.
on OP9 stromal cells in the presence of hematopoieticPCR analysis to detect rearrangements at the immuno-
cytokines to promote formation of HSCs that could beglobulin heavy chain and T cell receptor  loci showed
used for transplantation into Rag2/ isogenic mice. Ourthe presence of multiple rearranged alleles in the thymus
initial transplantation of hematopoietic derivatives ofand spleen of Rag2R/ ntES-derived mice, while no
Rag2R/ ntES cells into Rag2/ mice showed little torearranged alleles and only the germline allele were seen
no chimerism of the hematopoietic compartment as as-in mice derived from the original Rag2/ ntES line (Fig-
sessed by the numbers of GFP-positive cells in the pe-ures 3A and 4A). In addition, peripheral blood from
ripheral blood of recipient mice (data not shown). ThisRag2/ ntES- and Rag2R/ ntES-derived mice was
suggested that resistance to engraftment was a prop-compared to blood from a wild-type mouse by floures-
erty of the Rag2-deficient recipients and not the ntEScence-activated cell sorting (FACS) with antibodies
cells, because HoxB4-modified embryonic hematopoi-against markers for B cells (B220 and IgM) and T cells
etic stem cells engrafted in isogenic wild-type but not(CD4 and CD8) (Figure 3B). The relative numbers of B
Rag2-deficient recipients (not shown).and T cells detected in Rag2R/ ntES mice were compa-
rable to the B and T cell populations in wild-type mice;
in contrast, blood from mice derived from the parental Host NK Cells Present a Barrier to Engraftment
of Hematopoietic Progeny of the ntES CellsRag2/ ntES line showed essentially no mature B and
T cells. This proved that the repaired Rag2 allele could Yolk sac hematopoietic progenitors, which are closely
related to EB-derived progenitors, have lower major his-restore normal TCR and immunoglobulin rearrangements
and enable B and T cell production during normal devel- tocompatability complex (MHC) expression than bone
marrow-derived HSCs (Cumano et al., 2001; Huang andopment of mice derived by tetraploid embryo comple-
mentation. Auerbach, 1993), and it is known that hematopoietic
cells with low MHC expression are a target for NK cell-The mice derived from the repaired ES cells were used
Nuclear Transplantation Therapy with Gene Repair
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Figure 3. Analysis of Lymphoid Cells from
“Repaired” Mice and Mice Engrafted from
“Repaired” Donors
(A) PCR analysis for rearrangments at the
TCR  locus. PCR products amplified from
thymus DNA from tetraploid embryo comple-
mentation-derived neonatal mice were elec-
trophoresed on a 1.5% agarose gel, stained,
and photographed. Recombination products
of TCR D2J2 elements are shown using
primers 5 and 7 (Whitehurst et al., 1999). Filled
triangles indicate rearranged alleles; open tri-
angle indicates germline unrearranged allele.
Last lane shows 100 bp ladder (New England
Biolabs).
(B) FACS analysis of mature B and T cells in
peripheral blood. Peripheral blood was ob-
tained from a wild-type mouse (WT) and ntES
cell-derived mice and was immunostained
with antibodies against B cell markers, PE-
B220 and FITC-IgM (top row, as indicated),
or against T cell markers, FITC-CD4 and PE-
CD8 (bottom row, as indicated). The percent-
age of gated lymphoctes in each quadrant is
shown.
(C) FACS analysis of peripheral blood from
129B6F1 Rag2/ mice engrafted with neo-
nate blood or bone marrow (from a 28-day-
old mouse) from Rag2R/ ntES-derived mice.
The samples were stained with FITC-B220,
PE-CD4, and PE-CD8 antibodies. The FACS
plots show the percentages of gated periph-
eral blood mononuclear cells (PBMCs).
mediated rejection (Bix et al., 1991). Indeed, expression demonstrating that the repaired ntES cells contributed
to the B cell lineage. However, staining for IgM-positiveof the two class I MHC genes (H2-KB and H2-DB) was
significantly lower in the Rag2R/ ntES-derived HSCs B cells and mature CD4- and CD8-positive T cells was
essentially negative (data not shown). Analysis of thesethan in bone marrow (not shown). Therefore, it appeared
possible that enhanced NK activity in Rag2 mutant re- mice showed persistence of NK1.1-positive cells in pe-
ripheral blood, suggesting that immunodepletion wascipients was preventing engraftment of ES cell-derived
HSCs. inefficient and incomplete. Therefore, in the second ap-
proach, we engrafted hematopoietic derivatives of theWe tested this hypothesis using two different ap-
proaches. First, pretreatment of the Rag2/ mice with Rag2R/ ntES cells into Rag2/ recipients with a com-
plete absence of NK cells due to deletion of the IL2an anti-NK1.1 antibody that depletes NK cells responsi-
ble for the phenomenon of hybrid resistance prior to common cytokine receptor  chain (C) (Mazurier et al.,
1999). This strategy has recently been shown to enhancetransplantation (Kung and Miller, 1995; Lee et al., 1996)
resulted in low-level reconstitution of hematopoietic engaftment of definitive intraembryonic populations of
hematopoietic progenitors (Cumano et al., 2001). FACScells in the peripheral blood as assessed by FACS
(1.5%; Figure 4A, upper left). A small minority of these analysis of PBMCs from these double-mutant animals
transplanted with the Rag2R/ ntES cells showed es-cells stained with B220 antibody (0.13% of total PBMC),
Cell
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Figure 4. Functional Analysis of ntES Cell-Engrafted Mice
(A) FACS analysis of peripheral blood. GFP intensity is shown along the x axis, and the PE conjugated B220, GR1, IgM, CD4, or CD8 antibody
fluorescence is shown on the y axis. Percentage of gated mononuclear cells is shown in each quadrant.
(B) PCR was performed to detect the repaired Rag2R allele. The primers KH1 and KH2 flank the SalI site where the loxP-flanked selectable
marker CMVHygtk was inserted (Figure 1). The wild-type () and unrepaired (–) Rag2 alleles give a 200 bp product, while the repaired allele
(R) gives a 400 bp band. The left two sample lanes show controls from ES cell DNA (–/– ntES; R/–) followed by spleen (S), thymus (T), bone
marrow (BM), and peripheral blood (P) DNA samples isolated from Rag2 null (/), wild-type (WT), and repaired ntES tetraploid embryo
complementation (R/ 4n) mice; the next four lanes show samples from a Rag2/, C/ mouse engrafted with repaired ES cells (R/
ntES); and the last two lanes show samples from Rag2/ mice engrafted with neonate blood or bone marrow donated from a repaired ntES
tetraploid complementation mouse.
(C) PCRs were performed to detect IgH (upper gel) (Schlissel et al., 1991) and TCR (primers 1 and 4; lower gel) (Whitehurst et al., 1999)
rearrangments in spleen (S), thymus (T), or peripheral blood (P) DNA isolated from Rag2 null (/), wild-type (WT), and Rag2R/ (ntES tetraploid
embryo complementation) mice and a Rag2/, C/ mouse engrafted with repaired ES cells (R/ ntES). The last lanes show samples from
Rag2/ mice engrafted with neonate blood or bone marrow donated from repaired ntES tetraploid complementation mice. DNA (50 ng) was
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sentially complete donor chimerism (95% GFP-positive individual using a combination of reprogrammed somatic
cell therapy, often designated as “therapeutic cloning”PBMC; Figure 4A, Rag2, C null graphs), with predomi-
or “nuclear transplantation therapy” (Vogelstein et al.,nantly myeloid repopulation as shown by extensive
2002), and gene therapy. The procedure involved thestaining with GR1, a marker for granulocytes (94%; Fig-
isolation of tail-tip cells from mutant mice that are se-ure 4A, third graph), and limited staining with B220, a
verely immune deficient due to the mutation of the Rag2marker for B cells (2.4%; Figure 4A, second graph). FACS
recombinase gene. Nuclei from mutant tail tip cells wereanalysis detected a low level of GFP-positive, mature
transferred into enucleated oocytes, and ES cells wereB cells by IgM staining (0.74%) and GFP-positive, ma-
derived from one of the cloned blastocysts. Standardture T cells by CD4 and CD8 staining (0.09% and 0.38%,
homologous recombination was used to correct therespectively). The detection of lymphocytes in the pe-
gene defect in the ntES cells. To assess whether theripheral blood suggested that some lymphoid progeni-
genetic manipulation restored recombinase function,tors derived from the ntES cells were maturing in the
we derived mice from the repaired ntES cells by tetra-engrafted mice.
ploid embryo complementation. The lymphoid compart-To ensure that the engrafted cells in the double-mutant
ment of these animals consisted entirely of the repairedmice were derived from the repaired ntES cells, we per-
ES cells and was normal, as demonstrated by B andformed PCR analysis to detect the Rag2R allele. The
T cell numbers that are typical for wt mice. As expected,repaired allele was detected in DNA isolated from hema-
Rag2 mutant mice that were transplanted with bonetopoietic tissues of mice transplanted with in vitro differ-
marrow from the ntES cell-derived mice showed a com-entiated ES cells or neonate blood/bone marrow from
plete restoration of immune function. Thus, homologousntES-derived mice by tetraploid embryo complementa-
recombination in the ntES cells corrected the genetiction (Figure 4B). In contrast, the repaired allele was ab-
defect in the donor Rag2 mutant mouse strain.sent in DNAs from wt and Rag2/ control animals (Fig-
A critical step in nuclear transplantation therapy is theure 4B).
derivation in vitro of functional somatic cells from theTo confirm that the proper rearrangements necessary
cloned ES cells that can be used for transplantation intofor B and T cell function had occurred in transplanted
the diseased individual. As shown in the accompanyingdouble-mutant mice, PCR analyses of IgH and TCR loci
paper, expression of the homeobox gene HoxB4 en-were performed on lymphoid organs of a mouse 3.5
ables embryonic hematopoietic stem cells to stably en-weeks after transplantation. Multiple rearranged alleles
graft and chimerize long-term the lymphoid and myeloidwere detected, indicating that the transplanted ntES cell
lineages of transplanted mice (Kyba et al., 2002 [thisderivatives gave rise to polyclonal reconstitution of the
issue of Cell]). Here we have applied the principles de-B and T cell compartments (Figure 4C, ntES graft). The
fined in the accompanying report to generate HSCs fromlevel of TCR  gene rearrangement was about 20% of
the repaired ntES cells. As discussed below, we havethat seen in Rag2R/ ntES mice, derived by tetraploid
confronted two challenges in treating the immunodefi-embryo complementation, or wt mice. Levels of detect-
ciency in our model. First, our attempts at hematopoieticable IgH gene rearrangement in the spleen were much
repopulation were hindered by an engraftment barrier
lower, approximately 2% of wt. Moreover, we tested
peculiar to the Rag2-deficient recipients, which we have
serum of ntES cell-engrafted animals and controls for
linked to NK cell function. Second, the repaired cells
the presence of immunoglobulins of the IgM, IgG, and preferentially engraft the myeloid lineages and show a
IgA classes (Figure 4D). In contrast to the untreated relative block to T cell maturation by an as yet undefined
Rag2/, C/ control, all treated mice demonstrated mechanism. Therefore, while our initial attempts at ther-
the presence of serum IgM, IgG, and IgA. In agreement apeutic cloning have succeeded in restoring a modest
with the fewer peripheral blood lymphocytes in the ntES- degree of immune function, we have uncovered interest-
treated mice, serum Ig levels, particularly IgA, were ing and unanticipated biological principles that must be
lower than in controls. IgM levels were 10- to 15-fold more fully defined to make therapeutic cloning more
lower in the engrafted mice compared to wt, and IgG successful in this system. Our current state of under-
and IgA were approximately 125-fold lower. Thus, de- standing of these challenges is outlined below.
spite low levels of B and T cells in the peripheral blood The ntES cell-derived HSCs express low levels of MHC
of the Rag2/, C/ mice, some immune function was (not shown). Because it has been well established that
restored in the mice engrafted with in vitro repaired and low MHC expression on HSCs can lead to NK cell-medi-
differentiated ntES. ated graft rejection (Bix et al., 1991) and that Rag2-
deficient mice retain NK cell function, we tested whether
Discussion inhibition of NK activity would improve engraftment of
ES donor cell-derived HSCs into Rag2 recipients. Our
The goal of our work was to demonstrate the feasibility of initial pilot experiments with immunodepletion of NK
cells in the Rag2/ mice prior to transplantation re-correcting a genetic defect in somatic cells of an affected
used as template for each reaction, except for the amplification of IgH alleles from the ntES-transplanted mouse (500 ng). Filled triangles
indicate rearranged alleles; open triangle indicates germline unrearranged allele; M, 100 bp ladder (New England Biolabs).
(D) Enzyme-linked immunosorbent assays (ELISA) for IgM, IgG, and IgA. Fold dilution of serum is shown on the x axis; optical density (OD)
is shown on the y axis; each point represents the average of duplicates. , Rag2/, C/ mouse; , H17009, Rag2/, C/ mice engrafted with
repaired ntES cells; , Rag2–/– mouse engrafted with neonate blood from a repaired ntES tetraploid complementation mouse; , wt B6129F1
mouse).
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sulted in low-level engraftment of the in vitro derived in vitro expansion of a few successfully reprogrammed
HSCs (1.5% chimerism in PBMCs). In contrast, en- cells in an otherwise failing blastocyst. The ntES cells
graftment was essentially complete (95% peripheral derived from somatic cells have regained complete de-
blood chimerism) in a Rag2 null strain rendered devoid of velopmental potential (pluripotency), as evidenced by
NK cells by virtue of genetic deletion in the IL2 common the ability to derive mice through tetraploid embryo
cytokine receptor  chain (C) knockout. Our results complementation (Hochedlinger and Jaenisch, 2002).
raise the provocative possibility that even genetically The pluripotency of the ntES cells did not appear to be
matched cells derived by therapeutic cloning may still impacted by the genetic manipulation and the substan-
face barriers to effective transplantation for some dis- tial time in tissue culture required to execute their ge-
orders. netic repair. Thus, murine ES cells derived from “thera-
Despite high-level chimerism in the reconstituted peutic cloning” are highly proliferative and as facile to
Rag2/, C/ double-mutant mice, we have observed genetic manipulation as wt ES cells, making them an
a predominance of myeloid cells and a paucity of integral tool in studying cell replacement-based gene
lymphoid cells in the peripheral blood. Analysis of therapies.
lymphoid organs has shown extensive chimerism of the Our results constitute comprehensive proof of princi-
thymus and spleen and evidence of TCR and IgH gene ple approach that combines therapeutic cloning with
rearrangement, respectively, suggesting a blockade to gene and cell therapy to repair a genetic disorder. This
release of the lymphoid populations into the peripheral methodology could be adapted to a number of genetic
circulation. For several reasons, we believe that this disorders of the hematopoietic system that are currently
relative block to lymphoid differentiation is due to the treated by allogeneic marrow transplantation, including
retroviral-mediated constitutive expression of HoxB4 severe forms of hemoglobinopathy (sickle cell anemia,
and not to any specific defect in the repaired ntES cells. thalassemia) or marrow failure syndromes (Fanconi’s
The capacity for mature lymphoid development from anemia) in which the underlying genetic lesion is known.
the repaired ntES cells is clear from our observation of Because ES cells can be differentiated into many thera-
functional lymphoid reconstitution in the animals de- peutically relevant tissue types including neurons (Lee
rived from tetraploid embryo complementation. Further- et al., 2000), cardiac myocytes (Doevendans et al., 2000),
more, it has been shown previously that a fully functional and pancreatic  cells (Lumelsky et al., 2001), the strat-
lymphoid system can be reconstituted, albeit tran- egy employed here is applicable to a variety of genetic
siently, from in vitro differentiated ES cells (Potocnik et diseases that can be corrected by cell transplantation.
al., 1997). Similarly, human ES cells have been shown to be highly
Though original reports employing retroviral transduc- proliferative and to differentiate in vitro into cells such
tion of murine bone marrow with a HoxB4 retrovirus as neurons (Reubinoff et al., 2001; Zhang et al., 2001),
showed no disruption in hematopoiesis (Sauvageau et hematopoietic precursors (Kaufman et al., 2001), and
al., 1995), more recent data suggests that high-level cardiac myocytes (Kehat et al., 2001).
expression of HoxB4 by adenoviral transduction enhances The public debate over therapeutic cloning has em-
myeloid differentiation in a concentration-dependent man- phasized the theoretical potential to derive genetically
ner (Brun et al., 2001), and retroviral expression of the matched pluripotent cells from the somatic cells of a
related HoxB3 protein has been linked directly to inhibi- donor by nuclear transfer into enucleated oocytes. Gen-
tion of lymphoid differentiation (Sauvageau et al., 1997). erating genetically matched pluripotent stem cells for in
These reports corroborate our own experience that vitro differentiation into the desired cell type has several
shows the retroviral expression of HoxB4 in the in vitro potential benefits: (1) no requirement of long-term ad-
culture system to yield less consistent lymphoid recon- ministration of immunosuppressive drugs to prevent re-
stitution than the inducible expression system (Kyba jection of the transplanted cells, (2) the opportunity to
et al., 2002 [this issue of Cell]). High-level constitutive
repair genetic defects within stem cells to treat or cure
expression of HoxB4 may therefore drive hematopoietic
inherited diseases, and (3) the possibility to repeatedly
engraftment but skew differentiation away from the very
expand and differentiate the ntES cells into the desiredlymphoid populations we were attempting to restore.
cell type for continued therapy as needed. For futureThough enough maturation of lymphocytes occurs to
attempts using reprogrammed somatic cell therapyreconstitute some level of immunoglobulin in serum,
combined with gene therapy, it is crucial that the biologi-clearly the immune reconstitution is incomplete. Over-
cal and methodological constraints be defined that maycoming this problem might require engineering the in-
limit this method’s effectiveness for medical applica-ducible system for HoxB4 expression into the Rag2R/
tions.ntES cells or devising a differentiation protocol not de-
pendant on HoxB4. Experimental Procedures
The ability to derive pluripotent cells by NT is not
limited to a single species (Cibelli et al., 1998) and sug- NT and ES Cell Derivation
gests that derivation of human NT ES cells might be Tail-tip donor cells were cultured for 1–2 weeks from skinned and
macerated 1 cm pieces of 1-month-old male mice, Rag2/possible. It is of interest that while the efficiency of
(129B6F1). NT was performed as described (Wakayama et al., 1998).deriving ES cells from NT embryos is low (approximately
The reconstituted embryos were cultured in mCZB media until they2.2% from tail-tip cells [Wakayama et al., 2001]), it ap-
reach the blastocyst stage (generally 4 days), when they were trans-
pears to be greater than the efficiency of obtaining viable ferred into cultures of mouse embryonic fibroblasts in ES cell media
clones from NT embryos (0.5% from mouse tail-tip cells supplemented with 1000 U/ml LIF and 50 M of the MEK1 inhibitor,
[Wakayama et al., 1999]). The more efficient derivation PD098059. PD098059 has been shown to promote stem cell renewal
(Burdon et al., 1999). After 2–3 days in culture, most of these tail-of ntES cells than of viable animals may result from the
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tip cell-derived blastocysts remained unhatched and were treated Na2EDTA [pH 7.2]) prior to FACS analysis to remove red blood cells.
To detect B cells, 1 	 106 cells were stained with PE-B220 andwith acid tyrode’s solution to remove the Zona pelucida. After an-
other 4–5 days in culture, the proliferating ICM was dissociated and FITC-IgM or PE-IgM antibodies, and to detect T cells, with FITC-CD4
or PE-CD4 and PE-CD8 antibodies. Propidium iodide was added toplaced in a fresh well. After the cell line was passaged, PD098059
was no longer added to the media. exclude dead cells. All antibodies were purchased from Pharmingen.
FACS analyses were performed on a Becton-Dickinson cell sorter.
ELISA was done using the clonotyping kit from Southern Biotech-Gene Manipulation Methods
nology according to manufacturer’s specifications.We obtained the wild-type Rag2 locus by probing a BAC library
(RPCI-22 female 129Sv/EvTAC) with a Rag1 cDNA probe (the Rag1
and 2 loci are closely linked, approximately 10 kb apart). The NheI-
PCR AnalysisSpeI fragment (9.3 kb) containing the second and third exons of
Primers for detecting the Rag2R allele (KH1, TGCGAAGGGACTARag2 (from BAC clone 390 L-13) was subcloned, and a loxP-flanked
GATGGAC; KH2, CAACCATACGGGCTAGAAGC) were designed byHygtk selection cassette was inserted into a unique SalI site in the
the Primer 3 program (Rozen and Skaletsky, 1998), and amplifica-second intron. This targeting construct had 5 and 3 homologous
tions were performed on 50 ng of sample DNA in standard PCRarms of 3.2 and 6.1 kb, respectively.
conditions for Taq (GIBCO) for 34 cycles of 95
C, 30 s; 60
C, 30 s,Targeting was carried out as described. Briefly, 50g of construct
72
C, 30 s, followed by 72
C for 5 min. The residual sequences leftwas linearized (NotI) and electroporated into the ntES cells in
behind after Cre-mediated loop-out of the selectable marker resultHEPES-buffered saline (0.4 cm gap cuvette) with a single pulse of
in a 400 bp product for the repaired allele, while wt and mutant600V, 25 F. Hygromycin selection (140 g/ml) was started 24 hr
Rag2 alleles give a 200 bp band.after electroporation. Cre loop-out of the selectable marker was
Primers for TCR rearrangements were as described (Whitehurstdone by electroporating 10 g of pCrePAC plasmid into several
et al., 1999) using primer pairs 1 and 4, 1 and 7, or 5 and 7. Primerstargeted ntES cell lines. Gancyclovir (2 M final concentration) was
for PCR of IgH rearrangments (V to DJ) were as described (Schlisseladded 24 hr later.
et al., 1991); a mixture of three degenerate oligonucleotides (VH7183,DNA from ntES cell subclones was isolated as described (Laird
VH558, and VHQ52) and the J3 primer. TCR and IgH PCRs wereet al., 1991). Restriction enzyme digestions were done according to
performed in standard Taq conditions (GIBCO) for 35 cycles of 95
C,the suppliers’ guidelines (NEB) on 10 g of DNA overnight. Diges-
1 min; 62
C, 1 min; and 72
C for 2.5 min. All PCR products weretions were electrophoresed on 0.85% agarose gels in 0.5 	 TBE,
anaylzed by gel electrophoresis in 1.5% agarose, 0.5	 TBE andblotted to nylon membranes (GenescreenPlus), and probed in
stained with ethidium bromide.Church buffer (Church and Gilbert, 1984).
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